Thus, it is conceivable that pre-existing upregulation of DPP4 increased susceptibility to post-COVID-19 syndrome via increased viral entry (i.e., reverse causation), rather than DPP4 upregulation occurring in response to COVID-19. The gene discussed is DPP4; the disease is COVID-19.